loading
前日終値:
$4.51
開ける:
$4.51
24時間の取引高:
10,831
Relative Volume:
0.05
時価総額:
$231.46M
収益:
$84.82M
当期純損益:
$-21.43M
株価収益率:
-9.0918
EPS:
-0.49
ネットキャッシュフロー:
$-27.23M
1週間 パフォーマンス:
-13.06%
1か月 パフォーマンス:
-3.04%
6か月 パフォーマンス:
-43.04%
1年 パフォーマンス:
-62.30%
1日の値動き範囲:
Value
$4.40
$4.525
1週間の範囲:
Value
$4.40
$5.24
52週間の値動き範囲:
Value
$3.55
$16.11

Y Mabs Therapeutics Inc Stock (YMAB) Company Profile

Name
名前
Y Mabs Therapeutics Inc
Name
セクター
Healthcare (1174)
Name
電話
646-885-8505
Name
住所
202 CARNEGIE CENTER, PRINCETON, NY
Name
職員
107
Name
Twitter
Name
次回の収益日
2025-03-04
Name
最新のSEC提出書
Name
YMAB's Discussions on Twitter

YMAB を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
YMAB
Y Mabs Therapeutics Inc
4.44 231.46M 84.82M -21.43M -27.23M -0.49
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
446.28 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
523.47 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
323.18 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
561.17 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
240.30 28.51B 3.81B -644.79M -669.77M -6.24

Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-04-22 ダウングレード BofA Securities Neutral → Underperform
2024-11-18 開始されました Oppenheimer Outperform
2024-08-16 開始されました Cantor Fitzgerald Overweight
2024-06-28 開始されました Truist Buy
2023-05-10 アップグレード Wedbush Neutral → Outperform
2023-04-03 ダウングレード Guggenheim Buy → Neutral
2023-01-27 ダウングレード Morgan Stanley Equal-Weight → Underweight
2023-01-05 ダウングレード Cowen Outperform → Market Perform
2022-12-02 ダウングレード BofA Securities Buy → Neutral
2022-10-31 ダウングレード JP Morgan Neutral → Underweight
2022-10-31 ダウングレード Wedbush Outperform → Neutral
2022-07-06 再開されました Canaccord Genuity Buy
2022-06-24 開始されました BMO Capital Markets Outperform
2022-02-03 再開されました Guggenheim Buy
2021-11-19 再開されました Morgan Stanley Equal-Weight
2021-11-16 ダウングレード JP Morgan Overweight → Neutral
2021-05-07 アップグレード BofA Securities Neutral → Buy
2021-04-23 再開されました Cowen Outperform
2021-03-22 再開されました JP Morgan Overweight
2021-01-15 ダウングレード BofA Securities Buy → Neutral
2020-11-09 繰り返されました H.C. Wainwright Buy
2020-05-05 開始されました Barclays Overweight
2020-05-01 開始されました Janney Buy
2020-04-29 開始されました Morgan Stanley Equal-Weight
2019-12-24 開始されました JP Morgan Overweight
2019-11-20 開始されました Guggenheim Buy
2019-09-04 開始されました Wedbush Outperform
2019-04-01 開始されました H.C. Wainwright Buy
2018-10-16 開始されました BTIG Research Buy
2018-10-16 開始されました BofA/Merrill Buy
すべてを表示

Y Mabs Therapeutics Inc (YMAB) 最新ニュース

pulisher
Jun 15, 2025

Cantor Fitzgerald Initiates Coverage of Y-mAbs Therapeutics (YMAB) with Overweight Recommendation - MSN

Jun 15, 2025
pulisher
Jun 13, 2025

Y-mAbs Therapeutics’ SWOT analysis: oncology biotech stock faces growth hurdles By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

Y-mAbs Therapeutics’ SWOT analysis: oncology biotech stock faces growth hurdles - Investing.com

Jun 13, 2025
pulisher
Jun 12, 2025

Millennium Management LLC Cuts Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 7,765 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate - Yahoo Finance

Jun 11, 2025
pulisher
Jun 11, 2025

(YMAB) Long Term Investment Analysis - news.stocktradersdaily.com

Jun 11, 2025
pulisher
Jun 09, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

Jun 09, 2025
pulisher
Jun 08, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by Bank of America Corp DE - Defense World

Jun 08, 2025
pulisher
Jun 05, 2025

BNP Paribas Financial Markets Has $38,000 Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Sold by Jane Street Group LLC - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

YMAB CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact the Firm’s Attorneys, Securities Class Action Pending - ACCESS Newswire

Jun 03, 2025
pulisher
Jun 02, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $179,000 Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World

Jun 02, 2025
pulisher
Jun 02, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by Deutsche Bank AG - Defense World

Jun 02, 2025
pulisher
May 30, 2025

Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Lowered to $15.00 at Oppenheimer - Defense World

May 30, 2025
pulisher
May 29, 2025

Clear Street Reaffirms Their Buy Rating on Y-Mabs Therapeutics (YMAB) - The Globe and Mail

May 29, 2025
pulisher
May 29, 2025

How the (YMAB) price action is used to our Advantage - news.stocktradersdaily.com

May 29, 2025
pulisher
May 29, 2025

Oppenheimer Adjusts Target Price for Y-mAbs Therapeutics (YMAB) - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Y-mAbs Therapeutics (YMAB) Target Price Lowered by Oppenheimer | YMAB Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Oppenheimer Adjusts Price Target on Y-mAbs Therapeutics to $15 From $20, Maintains Outperform Rating - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Cautious Outlook on Y-Mabs Therapeutics Due to Delayed Milestones and Early-Stage Pipeline - TipRanks

May 29, 2025
pulisher
May 29, 2025

Y-mAbs Therapeutics’ (YMAB) “Outperform” Rating Reaffirmed at Wedbush - Defense World

May 29, 2025
pulisher
May 28, 2025

Transcript : Y-mAbs Therapeutics, Inc.Special Call - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Wedbush Lowers Price Target on Y-mAbs Therapeutics to $18 From $21, Maintains Outperform Rating - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Y-Mabs Therapeutics Updates on Radiopharmaceutical Progress - TipRanks

May 28, 2025
pulisher
May 28, 2025

Y-mAbs Therapeutics Announces Positive Phase 1 Trial Results for GD2-SADA in Metastatic Solid Tumors and Expands Radiopharmaceutical Pipeline - Nasdaq

May 28, 2025
pulisher
May 28, 2025

Clinical Trial Success: Y-mAbs Breakthrough in Cancer Treatment Shows Promise with Novel Radiopharmaceutical - Stock Titan

May 28, 2025
pulisher
May 27, 2025

Y-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025 - MSN

May 27, 2025
pulisher
May 26, 2025

Y-mAbs Therapeutics, Inc. Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting - marketscreener.com

May 26, 2025
pulisher
May 26, 2025

Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting - The Manila Times

May 26, 2025
pulisher
May 26, 2025

Y-mAbs Therapeutics Presents GD2-SADA Data at Advances in Neuroblastoma Research Meeting - Nasdaq

May 26, 2025
pulisher
May 26, 2025

Y-mAbs Advanced Cancer Trial Breakthrough: Key Data Coming for Revolutionary GD2-SADA Treatment - Stock Titan

May 26, 2025
pulisher
May 23, 2025

Y-mAbs Therapeutics’ SWOT analysis: antibody innovator’s stock faces growth hurdles - Investing.com Canada

May 23, 2025
pulisher
May 23, 2025

Y-mAbs Therapeutics’ SWOT analysis: antibody innovator’s stock faces growth hurdles By Investing.com - Investing.com South Africa

May 23, 2025
pulisher
May 22, 2025

What is HC Wainwright’s Forecast for YMAB FY2026 Earnings? - Defense World

May 22, 2025
pulisher
May 22, 2025

HC Wainwright Issues Pessimistic Estimate for YMAB Earnings - Defense World

May 22, 2025
pulisher
May 20, 2025

Caligan Partners LP Increases Stake in Y-mAbs Therapeutics Inc - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Cut to $11.00 by Analysts at HC Wainwright - Defense World

May 20, 2025
pulisher
May 19, 2025

What 7 Analyst Ratings Have To Say About Y-mAbs Therapeutics - Benzinga

May 19, 2025
pulisher
May 19, 2025

H.C. Wainwright Adjusts Price Target for Y-mAbs Therapeutics (YM - GuruFocus

May 19, 2025
pulisher
May 18, 2025

Price T Rowe Associates Inc. MD Cuts Stock Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World

May 18, 2025
pulisher
May 18, 2025

FY2025 EPS Estimates for YMAB Increased by Analyst - Defense World

May 18, 2025
pulisher
May 16, 2025

Formulation Is Key For Y-mAbs' Self-Assembling Antibody - Bioprocess Online

May 16, 2025
pulisher
May 16, 2025

Earnings Update: Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts - simplywall.st

May 16, 2025
pulisher
May 16, 2025

Oppenheimer Has Lowered Expectations for Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price - Defense World

May 16, 2025
pulisher
May 16, 2025

Q2 EPS Estimates for Y-mAbs Therapeutics Cut by Wedbush - Defense World

May 16, 2025
pulisher
May 15, 2025

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates - MSN

May 15, 2025
pulisher
May 15, 2025

Y-mAbs Therapeutics’ Earnings Call: Mixed Sentiment and Future Outlook - TipRanks

May 15, 2025
pulisher
May 15, 2025

Y-mAbs Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

Y-mAbs Therapeutics (YMAB) Maintains "Outperform" Rating, PT Low - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World

May 15, 2025

Y Mabs Therapeutics Inc (YMAB) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Y Mabs Therapeutics Inc (YMAB) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Rossi Michael J
PRESIDENT & CEO
Mar 07 '25
Sale
5.20
3,917
20,368
137,083
Gad Thomas
CHIEF BUSINESS OFFICER
Mar 07 '25
Sale
5.23
10,810
56,536
202,721
$20.58
price down icon 0.29%
$36.03
price up icon 0.01%
$20.82
price down icon 2.33%
$99.35
price down icon 0.84%
$107.07
price up icon 0.55%
biotechnology ONC
$241.09
price down icon 0.43%
大文字化:     |  ボリューム (24 時間):